Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | ARNT | P27540 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343826 | 0.92 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL1344613 | 0.90 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL4754828 | 0.88 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL3976283 | 0.86 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL13983342 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL12135665 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL3037532 | 0.85 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL4086930 | 0.84 | CYP3A4 (0.50) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL3022832 | 0.82 | CYP3A4 (0.56) | CYP3A4CYP2C9CYP2C19KCNH2EPAS1 | |
| SCHEMBL2638669 | 0.82 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2C19RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329755-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | DUNN JAMES PATRICK | 2010-02-18 | — | — | US | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041648-A1 | METHODS FOR TREATING RETROVIRAL INFECTIONS | CCR5, CXCR4, CCR1 | CYP3A4 3060/4885CYP2C9 2972/4885CYP2C19 1500/4885 |
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | CYP3A4 2749/4885CYP2C9 3253/4885CYP2C19 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.